Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18988105 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | December 2024 | July 2025 | Allow | 7 | 1 | 0 | No | No |
| 18828652 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | September 2024 | April 2025 | Allow | 7 | 2 | 0 | No | No |
| 18672651 | Modified Nucleoside Phosphoramidites | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18597197 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18594712 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18441882 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | February 2024 | October 2025 | Allow | 20 | 1 | 0 | No | No |
| 18422333 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | January 2024 | September 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18417807 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | January 2024 | April 2025 | Allow | 15 | 1 | 0 | No | No |
| 18410236 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | January 2024 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18403174 | Sugar Derivatives and Uses Thereof to Prepare Novel Senolytic Agents | January 2024 | May 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18390347 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18515359 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | November 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18510128 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18503499 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | November 2023 | December 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18501779 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | November 2023 | August 2024 | Allow | 9 | 0 | 0 | No | No |
| 18492972 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | October 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18286151 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | October 2023 | October 2024 | Abandon | 12 | 1 | 0 | Yes | No |
| 18378097 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | October 2023 | January 2025 | Allow | 15 | 2 | 0 | No | No |
| 18477379 | METHODS OF SEQUENCING USING NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUP | September 2023 | December 2024 | Allow | 15 | 2 | 0 | No | No |
| 18467985 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | September 2023 | November 2024 | Allow | 14 | 1 | 0 | No | No |
| 18242688 | METHOD FOR PURIFYING A SODIUM ALGINATE POWDER FROM ENDOTOXINS AND ENDOGENOUS PYROGENS | September 2023 | January 2026 | Allow | 28 | 0 | 0 | No | No |
| 18240621 | OLIGOSACCHARIDE ANALYTICAL STANDARDS | August 2023 | July 2024 | Allow | 10 | 1 | 0 | No | No |
| 18264751 | HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVES | August 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18359297 | COMPOUNDS AND METHODS FOR TREATING DISEASE | July 2023 | August 2024 | Allow | 13 | 3 | 1 | Yes | No |
| 18272466 | PHARMACEUTICAL COMPOSITION FOR TREATING SEPSIS AND USE THEREOF | July 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18350195 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | July 2023 | December 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18215881 | SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOF | June 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18270117 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | June 2023 | March 2026 | Allow | 32 | 1 | 0 | No | No |
| 18257815 | METHODS OF TREATING MASTITIS WITH AN ORTHOSOMYCIN ANTIMICROBIAL COMPOUND | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18335136 | METHOD FOR PREPARING N-ACETYL-D-GALACTOSAMINE TRIPOLYMER PRECURSOR | June 2023 | October 2025 | Allow | 28 | 0 | 0 | No | No |
| 18208629 | UTILITY OF NEMATODE SMALL MOLECULES | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18266438 | GLYCOSYLATED HISTONE DEACETYLASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18330293 | CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON’S DISEASE | June 2023 | October 2024 | Allow | 16 | 1 | 0 | No | No |
| 18256058 | SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | June 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18143533 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | May 2023 | September 2024 | Allow | 17 | 2 | 1 | No | No |
| 18251273 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | May 2023 | January 2025 | Allow | 20 | 1 | 0 | No | No |
| 18140705 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | April 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18309773 | COMPOUND INCLUDING A HETEROATOM AND NUCLEOBASE | April 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18297398 | CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF | April 2023 | December 2023 | Allow | 8 | 2 | 0 | Yes | No |
| 18248007 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | April 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18192609 | 3-PHENOXYBENZOIC ACID-GLUCURONIC ACID CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | March 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18190171 | METHOD FOR PRODUCING HYDROXYALKYL ALKYL CELLULOSE | March 2023 | November 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 18040309 | SOPHOROLIPID-CONTAINING COMPOSITION HAVING EXCELLENT HANDLEABILITY | March 2023 | February 2026 | Allow | 37 | 0 | 1 | No | No |
| 18123645 | HYALURONAN CONJUGATE | March 2023 | March 2025 | Allow | 23 | 3 | 0 | Yes | No |
| 18044089 | SPERM MOTILITY IMPROVING AGENT AND SPERM MOTILITY IMPROVING METHOD | March 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18174474 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | February 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18172719 | 5'-MODIFIED CARBOCYCLIC RIBONUCLEOTIDE DERIVATIVES AND METHODS OF USE | February 2023 | January 2026 | Allow | 35 | 2 | 0 | No | No |
| 18021907 | 2',3'-Diacetyluridine Substituted With Acetoacetyl at the 5' Position | February 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18021753 | PROMOIETY STRATEGY TO ENHANCE DRUG ACTIVITY | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18100192 | SYNTHESIS OF AN ANTIVIRAL AZASUGAR TRIPHOSPHATE | January 2023 | October 2025 | Allow | 33 | 1 | 0 | No | No |
| 18016062 | 3-DEOXY-2-KETOALDONIC ACID NITROGEN-CONTAINING DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF | January 2023 | December 2025 | Abandon | 35 | 1 | 0 | No | No |
| 18015282 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18085645 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | December 2022 | June 2024 | Allow | 17 | 0 | 0 | No | No |
| 18068360 | SULFONE DERIVATIVES | December 2022 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18010146 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE | December 2022 | September 2025 | Allow | 34 | 1 | 0 | No | No |
| 17993937 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | November 2022 | January 2026 | Allow | 37 | 2 | 0 | No | No |
| 17927426 | GALECTIN-3 INHIBITORS | November 2022 | January 2025 | Allow | 26 | 1 | 0 | No | No |
| 17999080 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17998261 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | November 2022 | January 2025 | Allow | 26 | 1 | 0 | No | No |
| 17998295 | PROCESSES FOR PREPARING C-4 SUGARS AND KETOSE SUGARS | November 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 17922514 | PROTEOLYSIS TARGETING COMPOUND WITH TISSUE TARGETING CAPABILITY AND USE THEREOF | October 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 17922229 | COMPOSITIONS AND METHODS OF USE THEREOF | October 2022 | June 2025 | Allow | 31 | 0 | 0 | No | No |
| 17921653 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | October 2022 | December 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17921964 | HETEROCYCLIC GLP-1 AGONISTS | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17996613 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17964867 | Green Methods of Carbohydrate Acetylation | October 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17995945 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | October 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17995948 | SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E | October 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17915843 | POLYMERIC AMPHOTERIC SURFACTANT COMPOUND | September 2022 | August 2025 | Allow | 34 | 1 | 0 | No | No |
| 17915822 | METAL-CARBOHYDRATE COMPLEX | September 2022 | August 2025 | Allow | 35 | 1 | 0 | No | No |
| 17913920 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | September 2022 | January 2026 | Allow | 40 | 1 | 0 | No | No |
| 17932359 | RNA-Editing Oligonucleotides and Uses Thereof | September 2022 | July 2024 | Allow | 22 | 1 | 0 | No | No |
| 17901771 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | September 2022 | March 2025 | Allow | 31 | 1 | 1 | Yes | No |
| 17905142 | A METHOD FOR PREVENTING OR TREATING A CORNAVIRUS INFECTIOUS DISEASE | August 2022 | February 2026 | Allow | 42 | 1 | 0 | No | No |
| 17801340 | IMMUNOMODULATING O-HET/ARYL AZALIDES | August 2022 | May 2025 | Allow | 33 | 1 | 0 | No | No |
| 17800339 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | August 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17818856 | NUCLEIC ACID-PEPTIDE-NUCLEIC ACID CONJUGATE MOLECULES AND METHODS OF MAKING THE SAME | August 2022 | March 2026 | Allow | 43 | 1 | 1 | No | No |
| 17798397 | 3'-KETOGLYCOSIDE COMPOUND FOR THE SLOW RELEASE OF A VOLATILE ALCOHOL | August 2022 | June 2025 | Allow | 35 | 1 | 0 | No | No |
| 17883398 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANSINE-3', 5'-CYCLIC MONOPHOSPHATES | August 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17785312 | USES OF LIPOTEICHOIC ACID FROM BIFIDOBACTERIA | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17784797 | CONJUGATES BETWEEN A BIOPOLYMER AND A PHOTOACTIVATED ANTIMICROBIAL AGENT FOR COMBATING FUNGAL DISEASES OF AGRICULTURAL INTEREST AND METHODS FOR PRODUCING SAID CONJUGATES | June 2022 | February 2026 | Allow | 45 | 1 | 1 | No | No |
| 17836763 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | June 2022 | August 2024 | Allow | 26 | 2 | 0 | No | No |
| 17831461 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17832112 | COBALAMIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISEASES CAUSED BY LACK OF VITAMIN B12 SUPPLY | June 2022 | July 2025 | Allow | 37 | 1 | 0 | No | No |
| 17831460 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | June 2022 | November 2024 | Allow | 30 | 1 | 0 | No | No |
| 17824362 | Novel Immunodulating Small Molecules | May 2022 | December 2025 | Allow | 43 | 2 | 0 | No | No |
| 17779043 | COMPOSITION FOR PREPARING ALLULOSE AND METHOD FOR PREPARING ALLULOSE BY USING SAME | May 2022 | June 2025 | Allow | 37 | 1 | 0 | No | No |
| 17746632 | TERPENE O-GLYCOSIDES | May 2022 | September 2024 | Allow | 28 | 3 | 1 | No | No |
| 17771089 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | April 2022 | July 2025 | Allow | 39 | 1 | 0 | No | No |
| 17714241 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | April 2022 | December 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17762387 | PREPARATION METHOD OF A GLYCOSIDE COMPOUND | March 2022 | July 2025 | Allow | 40 | 1 | 0 | No | No |
| 17701399 | CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTION | March 2022 | February 2026 | Allow | 47 | 1 | 1 | No | No |
| 17761109 | SYNTHESIS OF GLYCOSPHINGOLIPIDS | March 2022 | December 2025 | Allow | 45 | 2 | 0 | No | No |
| 17694630 | APOE4 IMPAIRS MYELINATION VIA ALTERED CHOLESTEROL BIOSYNTHESIS AND TRANSPORT IN OLIGODENDROGLIA | March 2022 | December 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17694180 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | March 2022 | August 2024 | Allow | 29 | 2 | 0 | No | No |
| 17434331 | METHOD FOR PRODUCING GLYCAN, BUILDING BLOCK FOR GYLICAN SYNTHESIS, AND COMPOUND | March 2022 | May 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17638799 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | February 2022 | January 2025 | Allow | 35 | 1 | 0 | No | No |
| 17679104 | METHOD OF PRODUCING NUCLEIC ACID COMPOUND, AND NUCLEIC ACID COMPOUND | February 2022 | August 2025 | Allow | 41 | 1 | 0 | No | No |
| 17634512 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | February 2022 | January 2025 | Allow | 35 | 1 | 0 | No | No |
| 17665724 | METHODS FOR THE PREPARATION OF RIBOSIDES | February 2022 | August 2025 | Abandon | 42 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCINTOSH III, TRAVISS C.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 36.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MCINTOSH III, TRAVISS C works in Art Unit 1693 and has examined 327 patent applications in our dataset. With an allowance rate of 96.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner MCINTOSH III, TRAVISS C's allowance rate of 96.3% places them in the 86% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCINTOSH III, TRAVISS C receive 1.80 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MCINTOSH III, TRAVISS C is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +3.3% benefit to allowance rate for applications examined by MCINTOSH III, TRAVISS C. This interview benefit is in the 25% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 32.8% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 63.1% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 88% percentile among all examiners. Of these withdrawals, 72.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 53.8% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 22.0% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.